Haleon (HLN) Cash from Financing Activities (2021 - 2025)
Haleon's (HLN) quarterly Cash from Financing Activities came in at -$3.4 billion in Q4 2025, down 300.75% on a QoQ basis from -$841.5 million in Q4 2023.
Haleon (HLN) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Haleon (HLN) has 4 years of Cash from Financing Activities data on file, last reported at -$3.4 billion in Q4 2025.
- Quarterly Cash from Financing Activities changed N/A year-over-year to -$3.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.3 billion (changed N/A YoY) and the FY2025 annual result came in at -$4.2 billion, down 112.79% from the prior year.
- Cash from Financing Activities retreated to -$3.4 billion in Q4 2025, from -$841.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $10.5 billion in Q3 2022 to a low of -$3.4 billion in Q4 2025.
- A 4-year average of $3.1 billion and a median of -$841.5 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 1138.55% — and 2023, when it slumped 108.39%.
- Tracing HLN's Cash from Financing Activities over 4 years: stood at -$965.2 million in 2021, then surged by 1138.55% to $10.0 billion in 2022, then tumbled by 108.39% to -$841.5 million in 2023, then plunged by 300.75% to -$3.4 billion in 2025.
- The last three Cash from Financing Activities figures came in at -$3.4 billion (Q4 2025), -$841.5 million (Q4 2023), and $10.0 billion (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.37 Bn |
| Dec 31, 2025 | -3.37 Bn |
| Dec 31, 2023 | -841.50 Mn |
| Dec 31, 2023 | -841.50 Mn |
| Dec 31, 2022 | 10.02 Bn |
| Dec 31, 2022 | 10.02 Bn |
| Sep 20, 2022 | 10.52 Bn |
| Sep 20, 2022 | 10.52 Bn |
| Dec 31, 2021 | -965.18 Mn |
| Dec 31, 2021 | -965.18 Mn |